MX2019008076A - Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. - Google Patents
Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.Info
- Publication number
- MX2019008076A MX2019008076A MX2019008076A MX2019008076A MX2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A
- Authority
- MX
- Mexico
- Prior art keywords
- galactosidase
- fabry
- treatment
- therapeutic regimen
- alpha
- Prior art date
Links
- 102000005840 alpha-Galactosidase Human genes 0.000 title abstract 3
- 108010030291 alpha-Galactosidase Proteins 0.000 title abstract 3
- 238000011285 therapeutic regimen Methods 0.000 title 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442537P | 2017-01-05 | 2017-01-05 | |
| PCT/IL2018/050018 WO2018127920A1 (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008076A true MX2019008076A (es) | 2019-08-29 |
Family
ID=62790830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008076A MX2019008076A (es) | 2017-01-05 | 2018-01-05 | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12194079B2 (https=) |
| EP (1) | EP3565583A4 (https=) |
| JP (2) | JP2020504131A (https=) |
| KR (2) | KR20190103320A (https=) |
| CN (2) | CN110381987A (https=) |
| AU (1) | AU2018205891B2 (https=) |
| BR (1) | BR112019013920A2 (https=) |
| CA (1) | CA3048151A1 (https=) |
| CL (1) | CL2019001867A1 (https=) |
| IL (1) | IL267863A (https=) |
| MX (1) | MX2019008076A (https=) |
| NZ (1) | NZ755725A (https=) |
| WO (1) | WO2018127920A1 (https=) |
| ZA (1) | ZA201904850B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| AR120055A1 (es) * | 2019-06-11 | 2022-02-02 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
| CN116419759A (zh) * | 2020-11-13 | 2023-07-11 | 韩美药品株式会社 | 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途 |
| JP2023549323A (ja) * | 2020-11-13 | 2023-11-24 | ハンミ ファーマシューティカル カンパニー リミテッド | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| EP1503788B1 (en) * | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| EP1877099B1 (en) * | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2192924B1 (en) | 2007-08-20 | 2017-10-11 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| WO2011107990A1 (en) | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
| CN103443270B (zh) * | 2011-01-20 | 2017-06-06 | 普罗塔里克斯有限公司 | 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体 |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
-
2018
- 2018-01-05 EP EP18736643.0A patent/EP3565583A4/en active Pending
- 2018-01-05 WO PCT/IL2018/050018 patent/WO2018127920A1/en not_active Ceased
- 2018-01-05 BR BR112019013920A patent/BR112019013920A2/pt unknown
- 2018-01-05 KR KR1020197023039A patent/KR20190103320A/ko not_active Ceased
- 2018-01-05 KR KR1020247008410A patent/KR20240042110A/ko not_active Ceased
- 2018-01-05 CA CA3048151A patent/CA3048151A1/en active Pending
- 2018-01-05 AU AU2018205891A patent/AU2018205891B2/en active Active
- 2018-01-05 NZ NZ755725A patent/NZ755725A/en unknown
- 2018-01-05 CN CN201880016068.5A patent/CN110381987A/zh active Pending
- 2018-01-05 CN CN202410140178.XA patent/CN117959455A/zh active Pending
- 2018-01-05 US US16/476,084 patent/US12194079B2/en active Active
- 2018-01-05 JP JP2019536488A patent/JP2020504131A/ja active Pending
- 2018-01-05 MX MX2019008076A patent/MX2019008076A/es unknown
-
2019
- 2019-07-04 CL CL2019001867A patent/CL2019001867A1/es unknown
- 2019-07-04 IL IL267863A patent/IL267863A/en unknown
- 2019-07-24 ZA ZA2019/04850A patent/ZA201904850B/en unknown
-
2022
- 2022-12-01 JP JP2022192939A patent/JP2023022244A/ja active Pending
-
2025
- 2025-01-10 US US19/015,746 patent/US20250134968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3565583A1 (en) | 2019-11-13 |
| IL267863A (en) | 2019-09-26 |
| ZA201904850B (en) | 2022-04-28 |
| RU2019124280A (ru) | 2021-02-06 |
| CN110381987A (zh) | 2019-10-25 |
| JP2023022244A (ja) | 2023-02-14 |
| RU2019124280A3 (https=) | 2021-09-14 |
| JP2020504131A (ja) | 2020-02-06 |
| CA3048151A1 (en) | 2018-07-12 |
| US20250134968A1 (en) | 2025-05-01 |
| NZ755725A (en) | 2023-06-30 |
| KR20190103320A (ko) | 2019-09-04 |
| US12194079B2 (en) | 2025-01-14 |
| AU2018205891B2 (en) | 2024-11-07 |
| CL2019001867A1 (es) | 2019-10-04 |
| EP3565583A4 (en) | 2020-12-02 |
| BR112019013920A2 (pt) | 2020-02-04 |
| KR20240042110A (ko) | 2024-04-01 |
| WO2018127920A1 (en) | 2018-07-12 |
| AU2018205891A1 (en) | 2019-08-15 |
| CN117959455A (zh) | 2024-05-03 |
| US20200155654A1 (en) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perez et al. | Update on the use of immunoglobulin in human disease: a review of evidence | |
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| NZ800220A (en) | Methods of treating heart failure by administering omecamtiv mecarbil | |
| MX2019008076A (es) | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. | |
| MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| MX2023012271A (es) | Medicina terapeutica para enfermedades fibrosas. | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| EP4523745A3 (en) | Bis-choline tetrathiomolybdate for treating wilson disease | |
| AU2020231505A8 (en) | Sequential intravitreal administration of AAV gene therapy to contralateral eyes | |
| EP4316589A3 (en) | Treatment of patients with classic fabry disease | |
| MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| WO2021007314A3 (en) | Treatment of cancer | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| EP4324522A3 (en) | Methods of treating fabry patients having renal impairment | |
| MX2021002090A (es) | Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
| RU2417091C2 (ru) | Способ лечения артрозо-артритов |